|
KR20150079694A
|
|
Chimeric vaccine antigens against hepatitis c virus
|
|
KR20140042796A
|
|
Cyclic peptides with an anti-neoplasic and anti-angiogenic activity
|
|
AU2012100293A4
|
|
Use of APL-type peptide for treating intestinal inflammatory diseases and type 1 diabetes
|
|
KR20140044794A
|
|
Method for inducing resistance to diseases in plants
|
|
CN103370336A
|
|
Recombinant antibodies to the vascular endothelial growth factor (VEGF) which are obtained by means of mutagenesis of variable regions
|
|
WO2012072055A1
|
|
Use of pacap for treating viral infections in aquatic organisms
|
|
CA2775794A1
|
|
Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization
|
|
EP2364690A1
|
|
Orally administrable pharmaceutical pellet of epidermal growth factor
|
|
MX2011007033A
|
|
Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes.
|
|
CN102203118A
|
|
Peptide antagonist of interleukin-15 activity
|
|
CN102046798A
|
|
Amino acid and nucleic acid sequences for controlling pathogens
|
|
WO2009094955A2
|
|
Method for quantification of the dengue ns1 antigen on an immunochromatographic strip
|
|
KR20100093548A
|
|
Engineered pertactin variants for vaccine use
|
|
WO2009056075A1
|
|
Pharmaceutical composition containing protein nmb0873
|
|
CU23739A1
|
|
PHARMACEUTICAL COMPOSITION USING COMBINATIONS OF VARIANTS OF THE GONADOTROPIN LIBERATING HORMONE (GNRH) AS IMMUNOGEN
|
|
CN101808658A
|
|
Cell-penetrating peptides and use thereof bonded to biomolecules with therapeutic action
|
|
EP2168595A1
|
|
Pharmaceutical compositions containing the protein nmb1796
|
|
WO2008104133A1
|
|
Combination therapy for the treatment of chronic hepatitis b
|
|
WO2008052490A2
|
|
Peptide chimeric molecules having antiviral properties against viruses of the flaviviridae family
|
|
MX2009004765A
|
|
Recombinant antibodies against vascular endothelial growth factor (vegf).
|
